Objective The objective was to estimate the optimal screen-positive 1-hour 50 g glucose challenge test (GCT) threshold for gestational diabetes (GDM) and predictive characteristics of increasing screen-positive GCT threshold values (135-199 mg/dL) for GDM. Study Design It is a secondary analysis of a multicenter mild GDM study. At 24 to 30 weeks' gestation, women with elevated GCT (135-199 mg/dL) completed a diagnostic 3-hour oral glucose tolerance test (OGTT). A novel change-point analysis method was used to compare the GDM rates for the adjacent GCT values, delineating categories of changing risk such that values within categories have equal risk for GDM. Positive (PPV) and negative (NPV) predictive values for GDM were computed for increasing GCT cut-offs. Results In 7,280 women with both GCT (135-199 mg/dL) and OGTT results, 4 GDM riskequivalent GCT categories were identified with escalations at 144, 158, and 174 mg/dL
Gestational diabetes mellitus (GDM) complicates as many as 14% of pregnancies in the United States and is associated with adverse maternal and perinatal outcomes. [1] [2] [3] [4] [5] There is currently a lack of consensus regarding the optimal approaches to screen and diagnose GDM. 6, 7 There is a lack of agreement on the use of a one-or two-step diagnostic approach. The American Diabetes Association (ADA) with the International Association of Diabetes and Pregnancy Study Groups (IADPSG) adopted the use of the single-step 75 g 2-hour OGTT approach. 8, 9 However, in the United States, the two-step approach is still most commonly used in accordance with findings from the 2013 National Institutes of Health (NIH) consensus conference and the subsequent American College of Obstetricians and Gynecologists (ACOG) Bulletin on GDM. 4, 10, 11 In addition, for the twostep diagnostic strategy, the glucose level after a 1-hour 50-g glucose challenge test (GCT), which is best to identify women at risk for GDM, is controversial. [11] [12] [13] Positive screen cut-off values of 130, 135, or 140 mg/dL are variably used; 140 mg/dL is reported to detect 80% of women who will be diagnosed with GDM based on the 3-hour oral glucose tolerance test (OGTT), while a value of 130 mg/dL identifies 90% of such women. 2 The ACOG recommends a 1-hour 50-g screen-positive cut-off value of either 130 or 140 mg/dL. 11 A value of 216 mg/dL or greater has been associated with100% positive predictive value (PPV) for GDM, while a value of 200 mg/dL or greater (for which a diagnostic OGTT is often bypassed) has a PPV >90%.
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These data are from relatively old studies and contradict studies suggesting 100% PPV at GCT thresholds below 200 mg/dL. Given the lack of consensus concerning optimal cut-offs, relating more contemporary screening GCT results to OGTT results, diagnostic of GDM may estimate new screening values for which diagnostic testing may be omitted and an optimal threshold for a positive screen result. The purpose of this study was to evaluate abnormal GCT results, 135 to 199 mg/dL, as a screening test for the diagnosis of GDM using data collected in a GDM treatment trial. Specifically, we sought to estimate the optimal screen positive threshold for GDM and whether any abnormal GCT threshold values <200 mg/dL afford sufficient PPV (i.e., >90%) to diagnose GDM.
Materials and Methods
We conducted a secondary analysis of data collected from women enrolled as part of the multicenter GDM treatment trial supported by the Eunice Kennedy Shriver 
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) was used to partition abnormal GCT values into risk-equivalent categories for GDM.
15 Across the range from 135 to 199 mg/dL, the risks of GDM associated with the adjacent GCT values were computed and compared. In this way, the adjacent GCT values that showed statistically insignificant differences in the GDM risk were used to delineate the risk-equivalent GCT values. A modified dynamic programming algorithm was performed to achieve a global optimization for the partition of GCT range. More computational and statistical details have been described recently. 15 This is a novel application of changepoint analysis methods. Unadjusted and adjusted odds ratios (OR) were calculated for risk-equivalent categories. The OR was adjusted for maternal age, body mass index (BMI) at enrollment, and race/ethnicity. PPV, defined as the proportion of true positive among declared positives, and NPV, defined as the proportion of true negative among declared negatives, were also computed for increasing GCT cut-offs along the range of 135 to 199 mg/dL. A result was considered statistically significant if the p-value was less than 0.05, and the Bonferoni adjustments were made for multiple comparisons. For supplementary analyses to evaluate whether results differed for Hispanic and non-Hispanic subgroups, a likelihood ratio test was used. Analyses were performed with SAS statistical software (SAS Institute Inc, Cary, NC) and R (http://www.r-project. org/). The primary study was approved by the institutional review board at each participating center.
(all p-values <0.05). The PPV for GDM increased from 33 to 64% as GCT increased from 135 to 199 mg/dL, while the NPV decreased from 80 to 67%. 
Results
Out of 7,298 women who had OGTT (including the 958 diagnosed with mild GDM and randomized 5 ), a total of 7,280 women with paired elevated GCT (135-199 mg/dL) and OGTT results screened for the GDM trial constituted our study population. Their baseline characteristics are presented in ►Table 1. The majority of patients were of Hispanic ethnicity (51.5%); 20.9% were Black and 24.7% non-Hispanic White. The mean age was 27.4 years, and mean BMI was 30.7. Mean abnormal GCT result was 154.8 mg/dL. These characteristics differed significantly between patients with and without GDM. The risk of GDM based on the change-point analysis method is presented in ►Fig. 1. Altogether, four different GDM risk-equivalent categories, corresponding to risk escalation at GCT values of 144, 158, and 174 mg/dL, were identified (p < 0.05, Bonferroni adjusted). The risk of GDM was 20%, 28%, 42%, and 61% for GCT values within risk equivalent categories of 135 to 143, 144 to 157, 158 to 173, and 174 to 199 mg/dL, respectively. In ►Table 2, the unadjusted and adjusted OR (95% CI) for GDM associated with each risk-equivalent category of GCT relative to the first category (135-143 mg/dL) are given. There is a 1.6-to 6-fold increase in the risk of GDM with increasing GDM riskequivalent category. The PPV and NPV (and their 95% CI) for escalating screen-positive cut-offs from 135 to 199 mg/dL are shown in ►Fig. 2. The respective PPV and NPV values range from 35 and 80% for GCT value of 140 to 63 and 67% for GCT of 195 mg/dL. If we use a GCT cut-off of 144 as screen positive among the 7,280 patients with GCT 135 to 199, 1,957 (26.9%) with GCT < 144 would avoid a GTT. Of 2,421 patients with GDM, 389 (16.1%) with GCT < 144 will not be diagnosed with GDM.
In additional analyses, we evaluated whether our reported risk-equivalent GCT categories differed by Hispanic or non-Hispanic subgroups. We compared findings for each subgroup to the reported overall risk-equivalent GCT categories. Our findings in the Hispanic subgroup (p ¼ 0.168) and the non-Hispanic subgroup (p ¼ 0.149) did not differ significantly from the overall findings. We also evaluated whether the risk-equivalent GCT categories differed by obesity status (BMI ! 30 at enrollment versus BMI < 30 at enrollment). We compared findings for each subgroup to the reported overall risk-equivalent GCT categories. Our findings in the obese subgroup (p ¼ 0.059) and the nonobese subgroup (p ¼ 0.693) did not differ significantly from the overall findings.
Comment
Based on a novel application of change-point analysis method, we identified four risk-equivalent categories along the range of abnormal GCT values from 135 to 199 mg/dL. These riskequivalent GLT categories applied equally to both Hispanic and non-Hispanic subgroups. The risk or PPV for GDM increased from 20% for GCT category 135 to 143 mg/dL to 61% for GCT category 174 to -199 mg/dL. In addition, the PPVs corresponding to 5-unit increments of abnormal GCT values from 135 to 195 mg/dL ranged from 33 to 64% only. Therefore, no cut-off abnormal GCT value <199 mg/dL alone appeared sufficient (PPV > 90%) for the diagnosis of GDM without an OGTT. The equivalence in GDM risk of GCT values between 135 and 143 mg/dL based on the novel method suggests that a screen-positive cut-off as high as 144 rather than the empirical 140 (based on a 5-unit difference alone) should be evaluated as an alternative to 135 mg/dL. At the cut-off of 144, 26.9% of women who currently undergo GTT testing would not need to have the test, and the prevalence of 16.1% of women with a diagnosis of GDM would avoid the diagnosis.
In one study, a GCT screen-positive cut-off of 143 mg/dL yielded a sensitivity of 83% and specificity of 87%, while a cutoff of 135 mg/dL yielded a sensitivity of 100% and a specificity of 80%. Similar to our study, the probability of GDM for escalating screen-positive cut-offs ranged from 15% in the 135 to 144 mg/dL group to 50% in the 175 to 184 mg/dL group. However the probability of GDM was 100% when the GCT was >185 mg/dL, a finding that we do not replicate. No women were diagnosed with GDM in the GCT range of 130 to -134 mg/dL. 16 One study suggested that variation in screenpositive thresholds for the GCT based on a woman's risk score for GDM (determined by age, BMI, and race) would reduce the number of screening tests and increase the GDM detection rate. 17 However, this approach is not in common use in the United States. Our data from a large contemporary cohort suggest that GCT values <144 mg/dL confer GDM risk equivalent to risk associated with a GCT of 135 mg/dL. Our study has several limitations. We did not include patients with GCT results <135 or ! 200 mg/dL. This did not allow for an evaluation of continuous GCT in these ranges and limited the calculation of PPV and NPV applicable to the entire screened population. Also, we could not compare our findings to those for the common alternative GCT cut-off of 130 mg/dL for a screen-positive cut-off used by some providers. Our findings using a novel statistical application warrant further validation in a larger population. Of note, the study population did not include patients with a prior history of gestational diabetes or chronic hypertension, limiting the generalizability to these patients and non-U.S. cohorts with a different racialethnic make-up and less obesity.
The strengths of our study include the large number of contemporaneous women with elevation of GCT and the use of novel change-point analysis methodology to predict GDM. Thus, these findings are directly applicable to patients with elevated GCT.
There is currently a lack of consensus worldwide regarding whether the one-step (2-hour 75-g OGTT) versus a two-step (typically a 1-hour 50-g GCT and 3-hour 100-g OGTT) strategy for the diagnosis of GDM should be used. 13 The ACOG recommends that all pregnant women should be screened according to their history, clinical risk factors, or a laboratory screening test and that laboratory screening and diagnosis may be omitted for low-risk women. 11 Further, the ACOG recommends the two-step approach for those at high risk for GDM. 10 ,11 There appears to be poor agreement between the two tests, and more women are diagnosed with GDM based on the 3-hour OGTT (12% versus 5% in one study). 18 However, the screen-positive rates will vary depending on the threshold value used for the 1-hour GCT and 3-hour GTT. On the strength of large clinical trials and observational studies, the OGTT cutoffs based on the Fourth International Workshop-Conference are commonly used. 2, 5, 19 Several studies, including a randomized trial, also suggest that the two-step approach involves less cost.
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Overall, our results suggest that given the changes in GDM risk, cut-offs different from the traditional 5-unit increments should be considered for further evaluation of the GCT. Thus, 144 mg/dL, instead of 140 mg/dL, may be evaluated as an alternative to 135 mg/dL, for recommending an OGTT. Furthermore, no single abnormal value <200 mg/dL appears sufficient (without an OGTT) for the diagnosis of GDM. Given the relative linear association between levels of glycemia and adverse pregnancy outcomes, impact on pregnancy outcomes is also an important dimension to be considered in
